These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11346681)

  • 21. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
    Fornier M; Esteva FJ; Seidman AD
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New developments in chemotherapy of advanced breast cancer.
    Lebwohl DE; Canetta R
    Ann Oncol; 1999; 10 Suppl 6():139-46. PubMed ID: 10676565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
    Büchler P; Reber HA; Eibl G; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
    Int J Oncol; 2005 Oct; 27(4):1125-30. PubMed ID: 16142331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
    Meden H; Beneke A; Hesse T; Novophashenny I; Wischnewsky M
    Anticancer Res; 2001; 21(2B):1301-5. PubMed ID: 11396203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
    Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
    Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
    Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
    Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
    Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with trastuzumab (herceptin).
    Vogel CL; Franco SX
    Breast J; 2003; 9(6):452-62. PubMed ID: 14616939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
    Zhu ZL; Zhang J; Chen ML; Li K
    Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer.
    Crown J
    Oncologist; 2001; 6 Suppl 3():17-21. PubMed ID: 11346680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose scheduling--Herceptin.
    Leyland-Jones B
    Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.